COVID-19 Evidence presented by InpharmD™-logo

COVID-19 Evidence presented by InpharmD™

Health & Wellness Podcasts

Lit Covid lists more than 10,000 COVID-19 studies and hundreds more are added daily. We parse through them and give you the evidence you need to know here, every week.

Lit Covid lists more than 10,000 COVID-19 studies and hundreds more are added daily. We parse through them and give you the evidence you need to know here, every week.

Location:

United States

Description:

Lit Covid lists more than 10,000 COVID-19 studies and hundreds more are added daily. We parse through them and give you the evidence you need to know here, every week.

Language:

English


Episodes

Acute Kidney Injury in COVID-19 Patients After Hospital Discharge

4/8/2021
A retrospective, observational, cohort study conducted to compare the rate of change in estimated glomerular filtration rate (eGFR) after hospital discharge between patients with and without COVID-19 who experienced in-hospital acute kidney injury (AKI)

Duration:00:07:06

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Patients with COVID-19

4/2/2021
A randomized study conducted to determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) viral load in mild to moderate COVID-19

Duration:00:08:06

Dexamethasone in Hospitalized Patients with COVID-19

3/25/2021
A controlled, open-label trial conducted to report the results of the controlled, open-label Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial of dexamethasone in patients hospitalized with COVID-19.

Duration:00:07:14

Vitamin-D3 Supplementation and COVID-19

3/17/2021
A randomized multicenter, double-blind, parallel-group, placebo-controlled trial, conducted to investigate the effect of vitamin D administration on hospital length of stay and other relevant clinical outcomes and adverse events in hospitalized patients with moderate to severe COVID-19.

Duration:00:07:07

Effect of Zinc and Vitamin-C on Ambulatory Patients with COVID-19

3/5/2021
A randomized, multi-center, open-label, open-label, factorial clinical trial conducted to examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection.

Duration:00:06:29

Anaphylaxis after Pfizer Vaccine

2/26/2021
Early data suggests the incidence of true anaphylaxis to the Pfizer-BioNTech COVID-19 vaccine is rare (11.1 cases per million vaccine doses). Anaphylaxis is more common in women and persons with a history of allergies, and symptoms typically appear within 30 minutes of injection.

Duration:00:06:50

Association of Psychiatric Disorders and COVID-19

2/19/2021
A retrospective, observational, cohort study done to assess whether a diagnosis of a schizophrenia spectrum disorder, mood disorder, or anxiety disorder is associated with mortality in patients with COVID-19.

Duration:00:05:57

Preliminary Data on Johnson and Johnson Vaccine

2/8/2021
A randomized, multicenter, double-blind, placebo-controlled, phase 1/2a clinical trial to evaluate the safety, reactogenicity, and immunogenicity of Ad26.COV2.S - a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein

Duration:00:08:07

Clinical Characteristics of COVID-19 in Hematopoietic Stem-Cell Transplantation Recipients

2/1/2021
An observational cohort study performed to describe characteristics and outcomes of hematopoietic stem-cell transplantation (HSCT) recipients after developing COVID-19

Duration:00:08:15

Continuation versus discontinuation of RAAS inhibitors in hospitalized patients with COVID-19

1/25/2021
A prospective, randomized, open-label trial performed to evaluate whether continuation of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is beneficial or harmful in patients who are admitted to hospital with COVID-19.

Duration:00:05:32

Comparative Differences Between COVID-19 and Seasonal Influenza

1/19/2021
A cohort study done to comparatively examine differences in risk of clinical manifestations and death among people admitted to hospital with coronavirus disease 2019 (COVID-19) and seasonal influenza.

Duration:00:05:28

Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with COVID-19 and seasonal influenza: cohort study

1/19/2021
A cohort study done to comparatively examine differences in risk of clinical manifestations and death among people admitted to hospital with coronavirus disease 2019 (COVID-19) and seasonal influenza

Duration:00:05:19

Efficacy and Safety of the Moderna mRNA-1273 SARS-CoV-2 Vaccine to Prevent COVID-19

1/12/2021
A phase 3 randomized, stratified, observer-blinded, placebo-controlled trial to to assess the safety and efficacy of the mRNA-1273 vaccine in preventing SARS-CoV-2 infection.

Duration:00:09:30

Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19 (ACTT-2)

1/4/2021
A randomized, multicenter, adaptive, double-blind, placebo-controlled trial to evaluate whether the combination of baricitinib plus remdesivir was superior to remdesivir alone.

Duration:00:06:36

Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic

12/28/2020
A comparative study done to evaluate the fitted filtration efficiency (FFE) of various consumer-grade and improvised face masks, as well as several popular modifications of medical procedure masks that are intended to improve mask fit or comfort.

Duration:00:06:08

Simultaneous COVID-19 in Homozygous Twins

12/22/2020
A case report describing two monozygotic twins with different clinical courses, despite having the same environment and genomic factors.

Duration:00:06:30

Adjusted BMI and risk of death due to COVID-19

12/17/2020
A retrospective, cohort study conducted to determine the adjusted effect of body mass index (BMI), associated comorbidities, time, neighborhood-level sociodemographic factors, and other factors on risk for death due to COVID-19

Duration:00:06:00

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomized, double-blind, placebo-controlled, phase 2 trial

12/9/2020
A randomzied, double-blind, placebo-controlled, multicenter, phase 2, pilot trial conducted to determine whether inhaled SNG001 (recombinant interferon beta-1a) has the potential to reduce the severity of lower respiratory tract illness and accelerate recovery in patients diagnosed with COVID-19.

Duration:00:06:57

Bamlanivimab - SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

11/27/2020
The purpose of this study was to evaluate the efficacy and safety of LY-CoV555 (bamlanivimab) in patients with recently diagnosed mild or moderate COVID-19 in the outpatient setting

Duration:00:08:04

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

11/19/2020
What does the evidence says on the safety and immunogenicity of pfizer's potential vaccine - BNT162b2 - as compared to other candidates?

Duration:00:07:33